| Company/Division name | Emergent BioSolutions |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Gaithersburg |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | AstraZeneca & Johnson & Johnson Covid-19 vaccines |
| What domestic positive factors made reshoring more attractive? | Infrastructure, Under-utilized capacity, Other, Covid-19, import replacement |
